Kumar Nagarathinam

Dr. Kumar Nagarathinam

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2021 in Chemical Reviews
Verified
Journal Article
Open access
DDDavid Drew
David Drew
RNRachel A. North
Rachel A. North
KNKumar Nagarathinam
Kumar Nagarathinam
MTMikio Tanabe
Mikio Tanabe
The major facilitator superfamily (MFS) is the largest known superfamily of secondary active transporters. MFS transporters are responsible for transporting a broad spectrum of substrates, either down their concentration gradient or uphill using the energy stored in the electrochemical gradients. Over the last 10 years, more than a hundred different MFS transporter structures covering close to 40 members have provided an atomic framework for piecing together the molecular basis of their transport cycles. Here, we summarize the remarkable promiscuity of MFS members in terms of substrate recognition and proton coupling as well as the intricate gating mechanisms undergone in achieving substrate translocation. We outline studies that show how residues far from the substrate binding site can be just as important for fine-tuning substrate recognition and specificity as those residues directly coordinating the substrate, and how a number of MFS transporters have evolved to form unique complexes with chaperone and signaling functions. Through a deeper mechanistic description of glucose (GLUT) transporters and multidrug resistance (MDR) antiporters, we outline novel refinements to the rocker-switch alternating-access model, such as a latch mechanism for proton-coupled monosaccharide transport. We emphasize that a full understanding of transport requires an elucidation of MFS transporter dynamics, energy landscapes, and the determination of how rate transitions are modulated by lipids.

1 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
KNKumar Nagarathinam
Kumar Nagarathinam
YNYoshiko Nakada-Nakura
Yoshiko Nakada-Nakura
CPChristoph Parthier
Christoph Parthier
TTTohru Terada
Tohru Terada
NJNarinobu Juge
Narinobu Juge
MTMikio Tanabe
Mikio Tanabe
Multidrug resistance (MDR) poses a major challenge to medicine. A principle cause of MDR is through active efflux by MDR transporters situated in the bacterial membrane. Here we present the crystal structure of the major facilitator superfamily (MFS) drug/H+ antiporter MdfA from Escherichia coli in an outward open conformation. Comparison with the inward facing (drug binding) state shows that, in addition to the expected change in relative orientations of the N- and C-terminal lobes of the antiporter, the conformation of TM5 is kinked and twisted. In vitro reconstitution experiments demonstrate the importance of selected residues for transport and molecular dynamics simulations are used to gain insights into antiporter switching. With the availability of structures of alternative conformational states, we anticipate that MdfA will serve as a model system for understanding drug efflux in MFS MDR antiporters.

18 June 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
LSLuisa J. Ströh
Luisa J. Ströh
KNKumar Nagarathinam
Kumar Nagarathinam
TKThomas Krey
Thomas Krey
Numerous antibodies have been described that potently neutralize a broad range of hepatitis C virus (HCV) isolates and the majority of these antibodies target the binding site for the cellular receptor CD81 within the major HCV glycoprotein E2. A detailed understanding of the major antigenic determinants is crucial for the design of an efficient vaccine that elicits high levels of such antibodies. In the past six years, structural studies have shed additional light on the way the host’s humoral immune system recognizes neutralization epitopes within the HCV glycoproteins. One of the most striking findings from these studies is that the same segments of the E2 polypeptide chain induce antibodies targeting distinct antigen conformations. This was demonstrated by several crystal structures of identical polypeptide segments bound to different antibodies, highlighting an unanticipated intrinsic structural flexibility that allows binding of antibodies with distinct paratope shapes following an “induced-fit” mechanism. This unprecedented flexibility extends to the entire binding site for the cellular receptor CD81, underlining the importance of dynamic analyses to understand 1) the interplay between HCV and the humoral immune system and 2) the relevance of this structural flexibility for virus entry. This review summarizes the current understanding how neutralizing antibodies target structurally flexible epitopes. We focus on differences and common features of the reported structures and discuss the implications of the observed structural flexibility for the viral replication cycle, the full scope of the interplay between the virus and the host immune system and – most importantly – informed vaccine design.

4 July 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
AKAxel Künstner
Axel Künstner
JSJulian Schwarting
Julian Schwarting
HWHanno Witte
Hanno Witte
VBVeronica Bernard
Veronica Bernard
SSStephanie Stölting
Stephanie Stölting
NGNiklas Gebauer
Niklas Gebauer

25 November 2017
Verified
Book Chapter
Closed access
PDF file
FJFrank Jaenecke
Frank Jaenecke
YNYoshiko Nakada-Nakura
Yoshiko Nakada-Nakura
KNKumar Nagarathinam
Kumar Nagarathinam
SOSatoshi Ogasawara
Satoshi Ogasawara
KLKehong Liu
Kehong Liu
MTMikio Tanabe
Mikio Tanabe

6 December 2024 in Science Advances
Verified
Journal Article
Open access
KNKumar Nagarathinam
Kumar Nagarathinam
ASAndreas Scheck
Andreas Scheck
MLMaurice Labuhn
Maurice Labuhn
LSLuisa J. Ströh
Luisa J. Ströh
EHElisabeth Herold
Elisabeth Herold
TKThomas Krey
Thomas Krey
Hepatitis C virus (HCV) infection causes ~290,000 annual human deaths despite the highly effective antiviral treatment available. Several viral immune evasion mechanisms have hampered the development of an effective vaccine against HCV, among them the remarkable conformational flexibility within neutralization epitopes in the HCV antigens. Here, we report the design of epitope-focused immunogens displaying two distinct HCV cross-neutralization epitopes. We show that these immunogens induce a pronounced, broadly neutralizing antibody response in laboratory and transgenic human antibody mice. Monoclonal human antibodies isolated from immunized human antibody mice specifically recognized the grafted epitopes and neutralized four diverse HCV strains. Our results highlight a promising strategy for developing HCV immunogens and provide an encouraging paradigm for targeting structurally flexible epitopes to improve the induction of neutralizing antibodies.